| Oct 31 |
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
|
| Oct 30 |
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake
|
| Oct 20 |
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025
|
| Oct 9 |
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges
|
| Oct 9 |
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
|
| Oct 8 |
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
|
| Oct 7 |
BioAtla: Numerous Catalysts Coming In Q4
|
| Oct 4 |
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
|
| Oct 1 |
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
|
| Sep 23 |
BioAtla out-licenses BA3362 to Context Therapeutics
|
